Hba1c Analyzer Market Size 2023 Report by Market Dynamics, Emerging Market Trends and Business Strategis - Benzinga
| 086060 Stock | KRW 3,410 5.00 0.15% |
About 61% of GeneBioTech's investor base is looking to short. The analysis of current outlook of investing in GeneBioTech Co suggests that many traders are alarmed regarding GeneBioTech's prospects. The current market sentiment, together with GeneBioTech's historical and current headlines, can help investors time the market. In addition, many technical investors use GeneBioTech stock news signals to limit their universe of possible portfolio assets.
GeneBioTech |
Hba1c Analyzer Market Size 2023 Report by Market Dynamics, Emerging Market Trends and Business Strategis Benzinga
Read at news.google.com
 |
GeneBioTech Fundamental Analysis
We analyze GeneBioTech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GeneBioTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GeneBioTech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
GeneBioTech is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
GeneBioTech Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with GeneBioTech stock to make a market-neutral strategy. Peer analysis of GeneBioTech could also be used in its relative valuation, which is a method of valuing GeneBioTech by comparing valuation metrics with similar companies.
Peers
GeneBioTech Related Equities
| 025890 | Hankook Steel | 6.80 | ||||
| 025550 | Hankuk Steel | 2.03 | ||||
| 012620 | Wonil Special | 0.28 | ||||
| 026940 | Bookook Steel | 0.61 | ||||
| 133820 | Finebesteel | 0.88 | ||||
| 060370 | KT Submarine | 1.69 | ||||
| 020180 | Daishin Information | 2.17 |
Complementary Tools for GeneBioTech Stock analysis
When running GeneBioTech's price analysis, check to measure GeneBioTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneBioTech is operating at the current time. Most of GeneBioTech's value examination focuses on studying past and present price action to predict the probability of GeneBioTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneBioTech's price. Additionally, you may evaluate how the addition of GeneBioTech to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |